

THE FOLLOWING DOCUMENTS
ARE ATTACHED:
(Please do not remove)

ER 2989X 88

ER 3676X 88

SUBJECT:

ROUTING SLIP

TO:		ACTION	INFO	DATE	INITIAL
	1 DCI	X			<i>JW</i>
	2 DDCI				
	3 EXDIR				
	4 D/ICS				
	5 DDI		X		
	6 DDA				
	7 DDO				
	8 DDS&T				
	9 Chm/NIC		X		
	10 GC				
	11 IG				
	12 Compt				
	13 D/OCA				
	14 D/PAO				
	15 D/PERS				
	16 D/Ex Staff				
	17 EA/DCI		X		
	18 NIO/CN		X		
	19				
	20				
	21				
	22				
		SUSPENSE _____ Date			

Remarks

STAT

ER 88-3676X

Executive Secretary

30 Sept '88

Date

3637 (10-81)



NATIONAL DRUG POLICY BOARD

Washington, D.C. 20530


September 29, 1988

Dear Director Webster:

The next meeting of the National Drug Policy Board is set for October 3, 1988, at 1:00 p.m., in the Roosevelt Room, The White House. The President is scheduled to attend this meeting. This being the Chairman's first Policy Board meeting, we would very much appreciate your attendance. Enclosed are the agenda/fact sheet and the summary of minutes for the July 27, 1988 meeting.

If you or your staff have any questions regarding the meeting, please do not hesitate to contact me (633-3435).

Sincerely,



David Pickens
Executive Director

Enclosures

The Honorable William H. Webster
Director
Central Intelligence Agency
Washington, D.C. 20505

cc: The Honorable William R. Kotapish

B-713-TR



NATIONAL DRUG POLICY BOARD

Washington, D.C. 20530

AGENDA/FACT SHEET

National Drug Policy Board Meeting

Monday, October 3, 1988

1:00 P.M., Roosevelt Room

The White House

I. Introductory Remarks

II. 1988 Omnibus Drug Legislation

Alan Kranowitz, Assistant to the President for Legislative Affairs will review the current status of the 1988 Drug Bill.

Salvatore R. Martoche, Vice Chairman of the Drug Enforcement Coordinating Group and Dr. Ian MacDonald, Chairman of the Drug Abuse Prevention and Health Coordinating Group, will comment on the impact that the drug legislation may have regarding specific supply and demand strategies.

III. National Drug Policy Board Strategy Implementation Plans

Mr. Martoche and Dr. MacDonald will outline the process to audit the Strategy Implementation Plans of the Policy Board. As indicated to the Congress, the Policy Board Lead Agencies will review the Implementation Plans. The National Drug Policy Board Staff assessment of the drug strategies have begun with the submission of the Lead Agency's report.

IV. FY 1990, Drug Budget Review

Office of Management and Budget Director, Jim Miller, will outline the projections for the FY 1990 drug budgets.

V. International Drug Control Efforts

Secretary of State George Shultz recently traveled to South America.

Assistant Secretary for Inter-American Affairs, Elliott Abrams will provide background on the South American trip and the current situation.

Assistant Secretary for International Narcotics Matters Ann Wroblewski will discuss results of the experts' group meeting which was held as a follow-up to the Seven Industrial Nations Toronto Summit.

VI. Drug-Free America Week

Dr. Otis Bowen, Vice Chairman and Secretary of Health and Human Services will review the schedule of activities highlighting Drug-Free America Week scheduled for October 24 - 30, 1988.

VII. Closing Remarks

NATIONAL DRUG POLICY BOARD
Summary of Meeting
July 27, 1988

- I. Introductory Remarks. The Chairman convened the meeting at 3:00 P.M. Dr. Bowen, the Vice Chairman, made an opening statement thanking Mr. Meese for his extensive work on the front lines of the war on drugs, for his loyalty to the President and his contributions to the Administration's successes.
- II. Legislative Initiative Update. Mr. Keating summarized the progress achieved. He and Dr. Macdonald presented the NDPB's concept package on the Hill. They met with Alan Kronowitz, who agreed to lead the overall legislative effort with Mr. Keating and Dr. Macdonald as his principal resource people, along with other NDPB representatives. This working group will divide in five sub-groups and designate departments to lead development of specific proposals. The sub-groups will further subdivide according to issues.
- III. DOD Authorization Bill. Secretary Carlucci addressed the DOD Mission Statement and stated that DOD is capable of doing drug detection and monitoring, however there are resource problems. He also acknowledged that this will be a large task which will probably trigger some turf sensitivity. Thus, he explained that DOD has not sought this mission and that DOD will work fully with Customs and the Coast Guard in the development of implementation plans.
- Mr. Keating remarked that the DOD Mission Statement was agreed to by all parties, and that Customs and the Coast Guard had participated in the drafting of the statement. The Enforcement Coordinating Group has requested that Customs and the Coast Guard continue to lead the overall interdiction policy.
- Ms. Dawson (Transportation) asked that the Board devise a mechanism through which problems (if any should arise) can be solved. The Chairman proposed that the Coordinating Groups be that mechanism, but if the problems cannot be solved at that level the Board will meet quickly to resolve any disputes. The Board approved this proposal.
- IV. Public Health Service Proposal. Secretary Bowen proposed that Federal expertise be used to assist in the development of innovative drug treatment programs. Specifically the

proposal involves the use of underutilized medical facilities or those targeted for closure on military bases, as drug treatment centers. These centers would be operated under State/local control, with HHS (Public Health Service) technical assistance. Secretary Carlucci stated that DOD would be happy to cooperate in this matter. The Chairman and the Board gave their support to this proposal which HHS will begin to implement with DOD.

- V. Office of Workplace Initiatives. Dr. Bowen explained that the Office of Workplace Initiatives oversees the Federal government's drug-free workplace program. He stated that the Office is seriously in need of funding. It needs approximately \$ 1 million to cover the operating costs for the rest of this year and an additional \$2.8 million to be made available for 1989. He proposed that these costs be distributed among the various agencies based on their participation in the program. The Board unanimously approved this proposal and directed that it be submitted to OMB for clarification of each agency's share of the costs.
- VI. Drug-Free Workplace. Secretary Verity reported on the Department of Commerce's progress in its meetings with the private sector regarding drug-free workplaces. Mr. Verity was particularly impressed with Phillips Industries, which established a policy of zero tolerance in its plants. Commerce will begin a private/public partnership which will result in a program involving random drug testing, testing of all new employees and the promotion of employees generated interest in a drug-free workplace. The Chairman asked the Drug Prevention and Health Coordinating Group to coordinate this effort with other on-going projects.
- VII. President's Commission on AIDS Report. Dr. Macdonald reported that out of the report's 597 recommendations, chapter eight has 51 drug specific recommendations. He observed that most of these issues have already been addressed by the NDPB. On a separate subject Dr. Macdonald informed the Board that five or six States have not applied for drug treatment funds for FY88.
- VIII. Drug Eradication Issues. Mr. Keating informed the Board that President Garcia of Peru intends to start drug eradication, and the U.S. can help by providing herbicides. However, at the present time the company which produces the herbicide "Spike," will not sell it to the government. Mr. Keating noted that the Enforcement Coordinating Group has approved a resolution condemning the company, and asks the Chairman to invite the CEOs of several chemical manufacturing companies to come to Washington to discuss this issue. Other options proposed by the Coordinating Group included the purchase of the patent for the herbicide,

or if that is not possible the boycott of these companies' products by all governmental agencies.

Ms. Wrobleski informed the Board that State has been in contact with the company and that "Spike" is only one of the three chemicals being tested for use in Peru. Peru has not decided yet which chemical it will use.

Dr. Bowen explained that one chemical company might be willing to sell the formula to the government or to sell the chemicals to the government if it is willing to take responsibility for liability.

The Chairman summarized that testing of the chemicals will go forward, the companies should be encouraged to cooperate, and if talks with the leaders of these companies would be productive the Chairman will engage in such talks. He asked Mr. Keating to review the options and to make any necessary recommendations to the Policy Board.

The meeting concluded at 4:10 P.M.

EXECUTIVE SECRETARIAT
ROUTING SLIP

TO:

		ACTION	INFO	DATE	INITIAL
1	DCI	X			
2	DDCI		X		
3	EXDIR				
4	D/ICS				
5	DDI		X		
6	DDA				
7	DDO				
8	DDS&T				
9	Chm/NIC		X		
10	GC				
11	IG				
12	Compt				
13	D/OCA				
14	D/PAO				
15	D/PERS				
16	D/Ex Staff				
17	NIO/CN		X		
18	EA/DCI		X		
19	ER				
20					
21					
22					
		SUSPENSE	_____		
			Date		

Remarks

The DCI plans to attend, schedule permitting.
 The DDI will attend if DCI cannot. The Board
 secretary concurs in this arrangement.


 Executive Secretary

20 JUL 88

Date

STAT

3637 (10-81)



NATIONAL DRUG POLICY BOARD

Washington, D.C. 20530

July 19, 1988

Executive Registry

88-2989X

Dear Director Webster:

The next meeting of the National Drug Policy Board is set for July 27, 1988, for principals only, 3:00 p.m., in the Roosevelt Room, The White House. This meeting will immediately follow the Domestic Policy Council meeting. As this will be the Chairman's last Policy Board meeting, we would very much appreciate your attendance. Enclosed are the draft agenda and the summary of minutes for the June 23, 1988 meeting.

If you have any questions regarding the meeting, please do not hesitate to contact me (633-3435).

Sincerely,

David Pickens
Executive Director

Enclosures

The Honorable William H. Webster
Director
Central Intelligence Agency
Washington, D.C. 20505

cc: The Honorable William R. Kotapish



B-213-TR

DRAFT

PROPOSED AGENDA
NATIONAL DRUG POLICY BOARD
WEDNESDAY, JULY 27, 1988
3:00 P.M., ROOSEVELT ROOM
THE WHITE HOUSE

- I. Opening Remarks (Vice Chairman)
- II. Legislative Initiatives Update (Dr. Donald I. Macdonald and Mr. Francis A. Keating II)
- III. Public Health Service Proposal on Treatment (Vice Chairman)
- IV. Office of Workplace Initiatives (Vice Chairman)
- V. Domestic Eradication Plan (Mr. Francis A. Keating and Mr. John C. Lawn)
- VI. DOD Role (Mr. Francis A. Keating)
- VII. DOD Authorization Bill (Mr. Francis A. Keating)
 - Lead Role of DOD in Detection
 - Report to the Congress on Cost
- VIII. President Commission on AIDS Report (Dr. Donald I. Macdonald)
 - Recommendations Concerning Drug Treatment
- IX. Chemical Industry Issues (Mr. Francis A. Keating)
 - Eli Lilly - "Spike"
 - Chevron - Paraquat

DRAFT

NATIONAL DRUG POLICY BOARD
Summary of Meeting
June 23, 1988

- I. Introductory Remarks. The Chairman convened the meeting at 10:00 A.M. The summary of the May 27th meeting was approved by the Board. Chairman Meese announced that there would be no Administration drug bill, but instead the Policy Board would submit a "checklist" of proposals to the Bi-Partisan Legislative Task Force for consideration.
- II. Legislative Update. The Chairman introduced an Issue Paper containing priority items, identified by the Coordinating Groups, that fall within the six policy goals announced by the President in 1986. Mr. Meese then turned the floor over to the Coordinating Group Chairmen for discussion of their Group's proposals in the Issue Paper.
- o Dr. Macdonald addressed items contained under goals 1-3 and 6 that had been developed by the Demand side. Dr. Macdonald circulated two handouts; one with proposed additions or substitutions to the Issue Paper, the other entitled "High-Risk Youth Initiative Elements."
 - o Frank Keating summarized the law enforcement initiatives that comprise goals 4 and 5.

Ms. Wrobleski voiced State Department's opposition to passport marking and advised the Chairman that all of the International initiatives would require new funding. The Board noted State's concern on the passport marking, however the proposal was approved.

Chairman Meese asked for, and received, the Board's approval of the Issue Paper and to recommend the President's approval of these measures. The Chairman asked the Executive Director to modify the Issue Paper to reflect the Board's amendments and to prepare briefing books based on the Issue Paper for use by the Executive Legislative Task Force negotiators.

- III. Jack Lawn briefed the Board on the Domestic Cannabis Suppression Strategy and advised that during week of July 11th, the Chairman would publicly announce the strategy which has been named Operation Stop Crop. George Dunlop asked that the strategy reflect increased focus on the problem of marijuana cultivation on public lands, and proposed specific language for this change. Chairman Meese advised that the subject would be addressed in any of the

Administration's public statements concerning Operation Stop Crop. Chairman Meese directed Mr. Keating to meet with Messrs. Lawn and Dunlop to resolve any issues regarding cross designation of Forest Service personnel to investigate marijuana cultivation cases.

- IV. Marion Blakey, Director of Public Affairs for the White House summarized the June 16th meeting of the Public Advocacy Working Group.

The meeting ended at 11:05 A.M.

Central Intelligence Agency



Washington, D.C. 20505

19 SEP 1988

Dr. Donald Ian Macdonald
Deputy Assistant to the President
for Drug Abuse Policy
The White House
Washington, D.C. 20500

Dear Dr. Macdonald:

Please be advised that the Central Intelligence Agency has a fair and compassionate treatment policy for HIV-infected employees and an information, education and personnel management policy which is in full compliance with the Office of Personnel Management's (OPM) and the Center for Disease Control's (CDC) Guidelines for AIDS.

The Central Intelligence Agency requests an exemption from further reporting requirements relative to our policy and program on AIDS information, education and personnel management, due to the covert status of many of our employees and the sensitive nature of their occupations.

Sincerely,

[Redacted Signature]

R. M. Huffstutler
Deputy Director
for
Administration

STAT

DA/OMS/EXO/[Redacted] (retyped 14 Sep 88)

STAT

Distribution:

- Orig - Adse
- 2 - DDA
- 1 - ER
- 1 - D/MS Chrono
- 1 - D/MS File



B-213-1R